Phase II Trial of Anti-HER2 Treatment in HER2-enriched Early Breast Cancer Identified by PAM50 (HER2E-PAM, PAMILIA Study)

NCT04817540 | Recruiting Phase 2

• 1 other identifier: 3-2021-0026
• Study Type: interventional
• Target: 59
• Locations: 1 country
• Sites: 1

Brief Summary

In this study, we prospectively analyzed molecular subtyping through the PAM 50 test in HER2-negative (IHC1+ or 2+ (FISH/SISH-)) breast cancer patients. A phase 2 single arm study was designed to determine whether the addition of HER2-targeted treatment with treatment increases the pathologic remission rate.

Conditions

HER2 Enriched Subtype Breast Cancer, Herzuma, PAM50 Study

Outcome Measures

Primary Outcomes (1)

• pathologic complete response rate (%, ypT0/isN0)

  TPathologic Complete Response (pCR) rate, assessed as no evidence of invasive disease in excised surgical specimens of breast and/or axilla(ypT0/isYpN0), in participants who received at least 1 cycle of herzuma and taxane in HER2-enriched subtype breast cancer

  12 weeks

Study Arms (1)

Single arm, Herzuma arm

EXPERIMENTAL

Drug: Herzuma

Interventions

Herzuma DRUG

8mg/kg IVF loading dose at first cycle -\> 6mg/kg IVF at 2,3,4th cycle of each 21 day cycle

Single arm, Herzuma arm

Eligibility Criteria

• Age: 19 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Pathologically and cytologically documented unsectable/metastatic breast cancer that :
• A. has confirmed HER2 negative expression regardless hormone receptor status
• definition of HER2 negative breast cancer i) HER2 IHC 1+ without ISH or ii) HER2 IHC 2+ and ISH negative (average HER2 gene copy number \<4 signals/cell in single probe ISH or HER2/CEP17 ratio \<2.0 \& average HER2 gene copy number \<4 signals cell in dual-probe ISH)
• No prior treatment of stage II-III breast cancer
• HR+ \& HER2- breast cancer : cT1-4N1-3
• HR- \& HER2- breast cancer : cT1N1-3 or cT2-4N0-3
• No systemic metastasis confirmed by pathological or radiological evaluation
• Patients over 19 years
• Confirmed to HER2-enriched subtype by PAM50 study
• Available FFPE 15-20 slides for evaluating PAM50 study
• ECOG 0-1
• Adequate bone marrow functions i) Hemoglobin≥ 9g/dL ii) ANC ≥1,500/mm3 iii) Platelet ≥100,000/mm3
• Adequate renal functions i) creatinine : ≤ 1.5 x UNL or ii) creatinine clearance (Ccr) ≥ 50 ml/min by Cockroft formula
• Adequate liver functions i) Bilirubine : ≤ 1.5 x UNL ii) AST/ALT : ≤ 2.5 x UNL
• Adequate cardiac functions

You may not qualify if:

• \) History of previous treatments of ipsilateral or contralateral invasive breast cancer 2) Confirmation of systemic distant metastasis of breast cancer 3) History of other malignancy within the last 5 years, except curatively treated basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, less than 2cm of thyroid cancer (papillary, follicular, medullary).
• \) inflammatory breast cancer (cT4d) 5) bilateral breast cancer(except, multifocal or multicentric breast cancer) 6) occult breast cancer 7) History of positivity for hepatitis B surface antigen, hepatitis C virus, or human immunodeficiency virus (HIV) 8) Woman of childbearing potential who is not consenting to use highly effective methods of birth control (eg, true abstinence \[periodic abstinence (eg calendar ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception\], sterilization, or other non-hormonal forms of contraception) during treatment 9) Uncontrolled infections and other serious diseases or medical conditions 10) Uncontrolled hyeprtension or clinically active cardiovascular disease: for example, cerebrovascular accident or transient isschemic attack, unstable angina, myocaridal infarction within 6 months prior to enrolment. Have symptomatic congestive heart failure (CHF; New York Heart Association II-IV) or symptomatic or poorly controlled cardiac arrhythmia.
• \) Have any condition (eg, psychological, geographical, or medical) that does not permit compliance with the study and follow-up procedures or suggest that the patient is, in the investigator's opinion, not an appropriate candidate for the study 12) Patients who are hypesenstivie reaction to experimental drugs (doxorubicin, cyclophosphamide, paclitaxel, docetaxel, herzuma) 13) Peripheral neuropathy CTCAE v4.03 ≥ grade 2

Sponsors & Collaborators

• Gangnam Severance Hospital: lead

Study Sites (1)

Gangnam Severance Hospital

Seoul, 135720, South Korea

RECRUITING

Central Study Contacts

Jun Jeong

CONTACT

82-2-2019-4601; gsirb@yuhs.ac

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: March 25, 2021
• First Posted: March 26, 2021
• Study Start: September 1, 2021
• Primary Completion: March 30, 2024
• Study Completion (Estimated): March 30, 2027
• Last Updated: October 11, 2023

Record last verified: 2023-10

Locations

KR (1)